BCR-ABL tyrosine kinase inhibitors
What are BCR-ABL tyrosine kinase inhibitors?
BCR-ABL tyrosine kinase inhibitors inhibit the enzyme BCR-ABL tyrosine kinase, which is important in the pathogenesis of chronic myelogenous leukemia (CML).
Chronic myelogenous leukemia occurs due a single genetic abnormality, known as the Philadelphia chromosome. During the translocation when the Philadelphia chromosome is created, a fusion gene called BCR-ABL gene is formed. The BCR-ABL gene encodes for the BCR-ABL tyrosine kinase. The BCR-ABL positive cells in chronic myelogenous leukemia have increased proliferation and resistance to cell death.
BCR-ABL tyrosine kinase inhibitors are used to treat chronic myelogenous leukemia.
List of BCR-ABL tyrosine kinase inhibitors
| Drug Name | Avg. Rating | Reviews |
|---|---|---|
| imatinib systemic (Pro) Brand names: Gleevec, Imkeldi |
47 reviews | |
| nilotinib systemic (Pro) Brand names: Tasigna, Danziten |
40 reviews | |
| dasatinib systemic (Pro) Brand names: Sprycel, Phyrago |
27 reviews | |
| bosutinib systemic (Pro) Brand name: Bosulif |
7 reviews | |
| ponatinib systemic (Pro) Brand name: Iclusig |
2 reviews | |
| asciminib systemic (Pro) Brand name: Scemblix | No reviews | |
| For ratings, users were asked how effective they found the medicine while considering positive/adverse effects and ease of use (1 = not effective, 10 = most effective). | ||
See also
Medical conditions treated or associated with BCR-ABL tyrosine kinase inhibitors:
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.